Table 1 Characteristics of patients with and without positive ¹⁸F-choline PET/CT

N

54

40

14

Age at diagnosis (year)

62 (51–78)

61.5 (51–77)

62 (51–78)

0.57

Cancer characteristics

Initial PSA (ng/mL)

9.84 (4–180)

9.58 (4–180)

10.51 (4.26–180)

0.86

Initial Gleason score

7 (5–9)

7 (5–9)

7 (6–9)

0.40

Gleason score ≥7

36 (67)

TNM

0.79

 T11

11 (20.5)

8 (20)

4 (29)

 T2

18 (33)

13 (32.5)

5 (35.5)

 T3

24 (44.5)

19 (47.5)

5 (35.5)

Other T (is, x)

1 (2)

 N0

34 (63)

24 (60)

10 (71)

 N1

2 (4)

2 (5)

0

 N2

1 (2)

1 (2.5)

0

 Nx

17 (31)

13 (32.5)

4 (29)

D’Amico risk group

0.004

 High

38 (70.5)

31 (77.5)

7 (50)

 Intermediate

11 (20.5)

4 (10)

7 (50)

 Low

5 (9)

5 (12.5)

0

Initial treatment

0.12

 RP

23 (43)

16 (40)

7 (50)

 EBRT

28 (52)

23 (57.5)

5 (36)

 Other^a

3 (5)

1 (2.5)

2 (14)

PSA values

 PSA nadir (ng/mL)

0.31 (0.01–13.31)

0.30 (0.01–11.26)

0.50 (0.01–13.31)

0.40

 Pre-PET/CT PSA (trigger PSA)

7.85 (0.47–111.60)

9.14 (2.04–111.60)

4.25 (0.47–83.40)

0.015

 Relative PSA

6.05 (0.24–104.59)

8.06 (1.85–104.59)

2.34 (0.24–82.97)

0.0005

PSA kinetics

 PSAdt in the last 12 m before PET/CT (months)

5.4 (0.6–91.6)

4.7 (1.7–27.7)

7.7 (0.6–91.6)

0.15

 PSA velocity (ng/mL/year)

6.40 (0.50–104.40)

8.10 (0.60–104.40)

3.05 (0.50–86.10)

0.01

PET/CT

 ADT at time of PET/CT

12 (22)

11 (27.5)

1 (7)

0.11

 Time from initial treatment to PET/CT (months)

83 (4–222)

86 (4–222)

77 (11–123)

0.27